Developer docs
API playgroundTry for free, no card

Search company profiles

UltraSight

Full company profile

uuid0000i5b

Namestring
UltraSight
Legal namestring
UltraSight® Inc.
Websiteurl
ultrasight.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

UltraSight is a digital health company developing FDA-cleared AI software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. Its core technology is a geometrical deep learning model that analyzes the ultrasound video stream in real time, predicts probe position relative to the heart, and renders 3D guidance instructions on screen; an image quality assessment module gates image capture only when diagnostic thresholds are met. The platform consists of the UltraSight Echosystem as the foundational environment, the AI Guidance Software as the primary capability, the Echo Stewardship Platform for multi-device enterprise workflow deployment, and PVAD IQ as a specialized module for microaxial flow pump position assessment in critical care.

The company is commercialized as B2B enterprise software to health systems, hospitals, and emergency departments, with the software designed as an accessory that pairs with compatible point-of-care ultrasound hardware from OEM partners including Philips Lumify, Butterfly Network, and EchoNous Kosmos. Revenue is generated through subscription-style enterprise licensing to healthcare institutions and through a licensing/royalty stream from a joint venture with SELVAS Healthcare that holds exclusive rights to distribute and commercialize the technology in Korea and Southeast Asia. Multi-jurisdictional regulatory approvals (FDA 510(k) across three clearances, CE Mark, UKCA, KFDA, Israeli AMAR) and clinical validation through studies at Mayo Clinic, Cleveland Clinic, Brigham and Women's, Stanford, University of Chicago, Aurora St. Luke's, and Jefferson Health underpin the commercial proposition, which targets the structural shortage of cardiac sonographers and the rising volume of echocardiographic exams.

Short descriptiontext

UltraSight develops FDA-cleared AI software that guides non-expert clinicians to acquire diagnostic-quality cardiac ultrasound images at the point of care, licensing the platform to health systems and partnering with ultrasound OEMs including Philips, Butterfly Network, and EchoNous.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI ultrasound guidance, cardiac imaging software, focused cardiac ultrasound, medical AI software, real-time image guidance
Industry2 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
AI Cardiac Ultrasound Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1AI-Guided Cardiac Ultrasound Software License
TypeSubscription Recurring
Description

UltraSight's Real-Time Guidance software is designed as an accessory for point-of-care ultrasound systems and is licensed to healthcare institutions. The software pairs with compatible ultrasound devices to provide real-time guidance for cardiac image acquisition. Revenue is generated through licensing agreements with health systems, hospitals, and clinics that deploy the technology.

ultrasight.com
2Joint Venture Revenue - Asia Pacific
TypeLicensing Royalties
Description

UltraSight has formed a joint venture with SELVAS Healthcare for Korea and Southeast Asia. SELVAS Healthcare has exclusive rights to distribute and commercialize UltraSight's AI cardiac ultrasound technology in Korea. This represents a licensing/royalty revenue stream from the joint venture arrangement.

ultrasight.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

UltraSight develops AI-powered real-time guidance software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. The software analyzes the ultrasound video stream using geometric deep learning, predicts probe position relative to the heart, and provides 3D graphical guidance on probe maneuvering along with automated image quality assessment. It is designed as an accessory that pairs with compatible point-of-care ultrasound devices from partners such as Philips, Butterfly Network, and EchoNous, and is licensed to healthcare systems, hospitals, and OEMs worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 93-100% of patient exams achieved sufficient diagnostic quality for clinical evaluation
+7 more records
Product overview1 text field

UltraSight offers a unified AI-powered cardiac ultrasound platform centered on its Real-Time Guidance software, which enables any healthcare professional to perform diagnostic-quality echocardiography regardless of sonography experience. The platform consists of the UltraSight Echosystem as the core AI environment, with the AI Guidance Software as the primary capability, the Echo Stewardship Platform for enterprise workflow management, and PVAD IQ as a specialized module for microaxial flow pump assessment in critical care settings. The software pairs with compatible point-of-care ultrasound devices including Philips Lumify, EchoNous Kosmos, and Butterfly Network hardware.

Product and service4 records
1UltraSight AI Guidance Software (Real-Time Guidance)
CategoryAI Cardiac Ultrasound Guidance Software
Description

Real-time AI guidance software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. The software analyzes the ultrasound video stream using geometric deep learning and provides 3D graphical guidance on probe maneuvering, then assesses image quality before allowing capture. Licensed to health systems, hospitals, and OEM ultrasound partners.

2Echo Stewardship Platform
CategoryCardiac Ultrasound Workflow Platform
Description

AI-guided enterprise workflow solution enabling health systems to scale focused cardiac ultrasound (FoCUS) using their existing multi-vendor ultrasound fleet. Provides multi-device compatibility and reduces variability at point of care while maintaining diagnostic quality.

3PVAD IQ
CategoryCritical Care AI Imaging Module
Description

FDA-cleared AI-powered software module that analyzes ultrasound images to monitor positioning of percutaneous ventricular assist devices (PVADs) in critical care. Automatically identifies the aortic valve plane and pump inlet on transthoracic echocardiography and calculates insertion depth in centimeters with a mean absolute error of 0.42 cm.

4UltraSight Echosystem
CategoryAI Cardiac Ultrasound Platform
Description

Comprehensive AI-powered cardiac ultrasound platform encompassing the Real-Time Guidance software and supporting workflows for image acquisition, quality assessment, and clinical decision support across multiple care settings. Combines ultrasound video stream analysis with AI-guided probe maneuvering and image quality assessment.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-04-16
Description

UltraSight selected for ARC Landing Boston healthtech accelerator, providing access to clinical environments, regulatory support, strategic mentorship, and integration into ARC's global investment platforms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Clinical partnership with Jefferson Health in Philadelphia to conduct a study and pilot of UltraSight's AI-guided focused cardiac ultrasound technology. The pilot will evaluate whether AI-guided image acquisition can match traditional transthoracic echocardiography in rapidly assessing right-ventricular function in patients with suspected pulmonary embolism. Partially funded by Israel Innovation Authority through Jefferson-Israel 2025 Health Tech Pilot Program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-04
Description

Clinical study collaboration evaluating consonance between echocardiograms performed by non-sonographer healthcare professionals using UltraSight's AI Guidance Software versus experienced sonographers in patients with hypertrophic cardiomyopathy (HCM). Single-center pilot study enrolling up to 75 patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-04
Description

Prospective clinical study enrolling 140 patients presenting to emergency department with symptoms such as syncope or TIA. Trial compares diagnostic capability between software-guided FoCUS and comprehensive transthoracic echocardiography (TTE), evaluating concordance rates and impact on patient disposition.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-12
Description

UltraSight selected as inaugural participant in ASE Accelerator Program, gaining access to product feedback, research validation opportunities, regulatory guidance, and commercialization strategies from industry experts. ASE is the world's largest cardiac subspecialty organization representing interests of physicians, sonographers, and scientists.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-06-27
Description

UltraSight joined Butterfly Garden, an AI Marketplace launched by Butterfly Network. UltraSight aims to integrate and deploy its real-time AI guidance software on Butterfly's imaging platform for use with Butterfly's single-probe, whole-body handheld ultrasound system. The partnership targets expanding AI-guided cardiac imaging across point-of-care ultrasound devices.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-03
Description

UltraSight and Mayo Clinic are jointly developing algorithms for analyzing and interpreting cardiac ultrasound images. Mayo Clinic has invested in UltraSight and provides access to researchers, clinicians, and data. The collaboration aims to create an end-to-end solution for point-of-care ultrasound enhanced by AI capabilities. Mayo Clinic is also conducting multiple clinical studies validating UltraSight's technology.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-05
Description

Joint venture between UltraSight and SELVAS Healthcare (subsidiary of SELVAS Group, Korean-based global digital healthcare company) for introducing UltraSight's technology in Asia, beginning with Korea and Southeast Asian market. SELVAS Healthcare has exclusive rights to distribute and commercialize UltraSight's AI cardiac ultrasound technology in Korea. KFDA approval was granted to SELVAS Invision.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-06-23
Description

Partnership to integrate UltraSight's real-time AI guidance software with EchoNous' KOSMOS handheld ultrasound device. The goal is enabling healthcare professionals with no prior sonography training to accurately conduct echocardiographic examinations, with focus on chronic cardiac patient monitoring closer to patients.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Handheld ultrasound hardware partner (Butterfly Garden) that also develops its own AI guidance capabilities. Direct overlap with UltraSight as both a distribution channel and a potential competitor in point-of-care AI cardiac ultrasound.

TypeDirect peer
Description

AI echocardiography company focused on automated analysis and interpretation of cardiac ultrasound images. Targets similar cardiology customers and is pursuing FDA-cleared AI for echo interpretation, complementing UltraSight's acquisition-guidance focus.

TypeBroad incumbent
Description

Largest ultrasound incumbent with deep cardiology installed base and the Caption Health AI acquisition. Bundles hardware, AI, and enterprise cardiology workflows at scale that UltraSight must match or partner around.

TypeBroad incumbent
Description

Major ultrasound incumbent and UltraSight partner (Lumify integration). Owns AI ultrasound development capabilities and vast cardiology distribution — represents both the largest commercial opportunity and the most significant competitive threat.

TypeDirect peer
Description

Handheld/portable ultrasound manufacturer (KOSMOS device) integrated with UltraSight's AI guidance software. Competes in the same point-of-care cardiac ultrasound category and could develop internal AI alternatives.

6Dia Imaging Analysis
TypeEmerging player
Description

AI-powered cardiac ultrasound analysis company focused on automated quantification of echo parameters. Adjacent to UltraSight in the cardiac AI workflow — interpretation layer complementing UltraSight's acquisition layer.

TypeEmerging player
Description

AI-augmented cardiac auscultation (digital stethoscope) company pursuing FDA-cleared AI for cardiac disease detection. Adjacent point-of-care cardiology AI for primary/ambulatory use — potential upstream or downstream complement to UltraSight's imaging workflow.

8Caption Health (GE HealthCare)
TypeDirect peer
Description

Direct competitor in AI-guided cardiac ultrasound acquisition, originally founded to enable novice users to capture diagnostic-quality echocardiograms. Acquired by GE HealthCare in 2023, embedding the technology into a major incumbent's ultrasound portfolio — UltraSight's most direct substitute.

TypeEmerging player
Description

Cardiac MRI AI company enabling faster scan acquisition through automated guidance. Targets cardiology AI in a different modality but with parallel workflow philosophy and overlapping customer base in academic cardiology.

TypeEmerging player
Description

AI ultrasound simulation and guidance company, publicly traded on AIM. Addresses similar novice-user enablement for ultrasound acquisition with broader (non-cardiac) clinical scope, representing adjacent competition for hospital training budgets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

UltraSight

AI Cardiac Ultrasound Softwareultrasight.com

UltraSight develops FDA-cleared AI software that guides non-expert clinicians to acquire diagnostic-quality cardiac ultrasound images at the point of care, licensing the platform to health systems and partnering with ultrasound OEMs including Philips, Butterfly Network, and EchoNous.

What UltraSight does

UltraSight is a digital health company developing FDA-cleared AI software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. Its core technology is a geometrical deep learning model that analyzes the ultrasound video stream in real time, predicts probe position relative to the heart, and renders 3D guidance instructions on screen; an image quality assessment module gates image capture only when diagnostic thresholds are met. The platform consists of the UltraSight Echosystem as the foundational environment, the AI Guidance Software as the primary capability, the Echo Stewardship Platform for multi-device enterprise workflow deployment, and PVAD IQ as a specialized module for microaxial flow pump position assessment in critical care.

The company is commercialized as B2B enterprise software to health systems, hospitals, and emergency departments, with the software designed as an accessory that pairs with compatible point-of-care ultrasound hardware from OEM partners including Philips Lumify, Butterfly Network, and EchoNous Kosmos. Revenue is generated through subscription-style enterprise licensing to healthcare institutions and through a licensing/royalty stream from a joint venture with SELVAS Healthcare that holds exclusive rights to distribute and commercialize the technology in Korea and Southeast Asia. Multi-jurisdictional regulatory approvals (FDA 510(k) across three clearances, CE Mark, UKCA, KFDA, Israeli AMAR) and clinical validation through studies at Mayo Clinic, Cleveland Clinic, Brigham and Women's, Stanford, University of Chicago, Aurora St. Luke's, and Jefferson Health underpin the commercial proposition, which targets the structural shortage of cardiac sonographers and the rising volume of echocardiographic exams.

UltraSight firmographics

Firmographics
Name
UltraSight
Legal name
UltraSight® Inc.
Website
https://ultrasight.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
UltraSight develops FDA-cleared AI software that guides non-expert clinicians to acquire diagnostic-quality cardiac ultrasound images at the point of care, licensing the platform to health systems and partnering with ultrasound OEMs including Philips, Butterfly Network, and EchoNous.
Ownership category
akta.pro rank

UltraSight industry classification

Industry
Product category
AI Cardiac Ultrasound Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • AI ultrasound guidance
  • Cardiac imaging software
  • Focused cardiac ultrasound
  • Medical AI software
  • Real-time image guidance

Where UltraSight is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

UltraSight business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. AI-Guided Cardiac Ultrasound Software License: UltraSight's Real-Time Guidance software is designed as an accessory for point-of-care ultrasound systems and is licensed to healthcare institutions. The software pairs with compatible ultrasound devices to provide real-time guidance for cardiac image acquisition. Revenue is generated through licensing agreements with health systems, hospitals, and clinics that deploy the technology.
  2. Joint Venture Revenue - Asia Pacific: UltraSight has formed a joint venture with SELVAS Healthcare for Korea and Southeast Asia. SELVAS Healthcare has exclusive rights to distribute and commercialize UltraSight's AI cardiac ultrasound technology in Korea. This represents a licensing/royalty revenue stream from the joint venture arrangement.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

UltraSight product offering

Product offering

Core offering

UltraSight develops AI-powered real-time guidance software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. The software analyzes the ultrasound video stream using geometric deep learning, predicts probe position relative to the heart, and provides 3D graphical guidance on probe maneuvering along with automated image quality assessment. It is designed as an accessory that pairs with compatible point-of-care ultrasound devices from partners such as Philips, Butterfly Network, and EchoNous, and is licensed to healthcare systems, hospitals, and OEMs worldwide.

Product overview

UltraSight offers a unified AI-powered cardiac ultrasound platform centered on its Real-Time Guidance software, which enables any healthcare professional to perform diagnostic-quality echocardiography regardless of sonography experience. The platform consists of the UltraSight Echosystem as the core AI environment, with the AI Guidance Software as the primary capability, the Echo Stewardship Platform for enterprise workflow management, and PVAD IQ as a specialized module for microaxial flow pump assessment in critical care settings. The software pairs with compatible point-of-care ultrasound devices including Philips Lumify, EchoNous Kosmos, and Butterfly Network hardware.

Differentiator

Problem solved

Functional benefit

Products and services

  • UltraSight AI Guidance Software (Real-Time Guidance) Real-time AI guidance software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. The software analyzes the ultrasound video stream using geometric deep learning and provides 3D graphical guidance on probe maneuvering, then assesses image quality before allowing capture. Licensed to health systems, hospitals, and OEM ultrasound partners.
  • Echo Stewardship Platform AI-guided enterprise workflow solution enabling health systems to scale focused cardiac ultrasound (FoCUS) using their existing multi-vendor ultrasound fleet. Provides multi-device compatibility and reduces variability at point of care while maintaining diagnostic quality.
  • PVAD IQ FDA-cleared AI-powered software module that analyzes ultrasound images to monitor positioning of percutaneous ventricular assist devices (PVADs) in critical care. Automatically identifies the aortic valve plane and pump inlet on transthoracic echocardiography and calculates insertion depth in centimeters with a mean absolute error of 0.42 cm.
  • UltraSight Echosystem Comprehensive AI-powered cardiac ultrasound platform encompassing the Real-Time Guidance software and supporting workflows for image acquisition, quality assessment, and clinical decision support across multiple care settings. Combines ultrasound video stream analysis with AI-guided probe maneuvering and image quality assessment.

Quantifiable outcome

  • 93-100% of patient exams achieved sufficient diagnostic quality for clinical evaluation
  • +7 more outcomes

Companies that use UltraSight

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

UltraSight technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature6 records

UltraSight partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor and core.

  • ARC (Sheba Medical Center Innovation Arm)minorGTM or Marketing Partner · 16 April 2026UltraSight selected for ARC Landing Boston healthtech accelerator, providing access to clinical environments, regulatory support, strategic mentorship, and integration into ARC's global investment platforms.
  • Jefferson HealthcoreStrategic or Co-development Partner · 9 January 2026Clinical partnership with Jefferson Health in Philadelphia to conduct a study and pilot of UltraSight's AI-guided focused cardiac ultrasound technology. The pilot will evaluate whether AI-guided image acquisition can match traditional transthoracic echocardiography in rapidly assessing right-ventricular function in patients with suspected pulmonary embolism. Partially funded by Israel Innovation Authority through Jefferson-Israel 2025 Health Tech Pilot Program.
  • Cleveland CliniccoreStrategic or Co-development Partner · 4 September 2025Clinical study collaboration evaluating consonance between echocardiograms performed by non-sonographer healthcare professionals using UltraSight's AI Guidance Software versus experienced sonographers in patients with hypertrophic cardiomyopathy (HCM). Single-center pilot study enrolling up to 75 patients.
  • Brigham and Women's HospitalcoreStrategic or Co-development Partner · 4 September 2025Prospective clinical study enrolling 140 patients presenting to emergency department with symptoms such as syncope or TIA. Trial compares diagnostic capability between software-guided FoCUS and comprehensive transthoracic echocardiography (TTE), evaluating concordance rates and impact on patient disposition.
  • American Society of Echocardiography (ASE)coreStrategic or Co-development Partner · 12 March 2025UltraSight selected as inaugural participant in ASE Accelerator Program, gaining access to product feedback, research validation opportunities, regulatory guidance, and commercialization strategies from industry experts. ASE is the world's largest cardiac subspecialty organization representing interests of physicians, sonographers, and scientists.
  • Butterfly NetworkcoreTechnology or Integration · 27 June 2024UltraSight joined Butterfly Garden, an AI Marketplace launched by Butterfly Network. UltraSight aims to integrate and deploy its real-time AI guidance software on Butterfly's imaging platform for use with Butterfly's single-probe, whole-body handheld ultrasound system. The partnership targets expanding AI-guided cardiac imaging across point-of-care ultrasound devices.
  • Mayo CliniccoreStrategic or Co-development Partner · 3 June 2024UltraSight and Mayo Clinic are jointly developing algorithms for analyzing and interpreting cardiac ultrasound images. Mayo Clinic has invested in UltraSight and provides access to researchers, clinicians, and data. The collaboration aims to create an end-to-end solution for point-of-care ultrasound enhanced by AI capabilities. Mayo Clinic is also conducting multiple clinical studies validating UltraSight's technology.
  • SELVAS HealthcarecoreChannel Partner/ Reseller/ Distributor · 5 February 2024Joint venture between UltraSight and SELVAS Healthcare (subsidiary of SELVAS Group, Korean-based global digital healthcare company) for introducing UltraSight's technology in Asia, beginning with Korea and Southeast Asian market. SELVAS Healthcare has exclusive rights to distribute and commercialize UltraSight's AI cardiac ultrasound technology in Korea. KFDA approval was granted to SELVAS Invision.
  • EchoNouscoreTechnology or Integration · 23 June 2023Partnership to integrate UltraSight's real-time AI guidance software with EchoNous' KOSMOS handheld ultrasound device. The goal is enabling healthcare professionals with no prior sonography training to accurately conduct echocardiographic examinations, with focus on chronic cardiac patient monitoring closer to patients.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

UltraSight competitors and assessment

Company assessment

Direct peers

  • Butterfly Network: Handheld ultrasound hardware partner (Butterfly Garden) that also develops its own AI guidance capabilities. Direct overlap with UltraSight as both a distribution channel and a potential competitor in point-of-care AI cardiac ultrasound.
  • Ultromics: AI echocardiography company focused on automated analysis and interpretation of cardiac ultrasound images. Targets similar cardiology customers and is pursuing FDA-cleared AI for echo interpretation, complementing UltraSight's acquisition-guidance focus.
  • EchoNous: Handheld/portable ultrasound manufacturer (KOSMOS device) integrated with UltraSight's AI guidance software. Competes in the same point-of-care cardiac ultrasound category and could develop internal AI alternatives.
  • Caption Health (GE HealthCare): Direct competitor in AI-guided cardiac ultrasound acquisition, originally founded to enable novice users to capture diagnostic-quality echocardiograms. Acquired by GE HealthCare in 2023, embedding the technology into a major incumbent's ultrasound portfolio — UltraSight's most direct substitute.

Broad incumbents

  • GE HealthCare: Largest ultrasound incumbent with deep cardiology installed base and the Caption Health AI acquisition. Bundles hardware, AI, and enterprise cardiology workflows at scale that UltraSight must match or partner around.
  • Philips: Major ultrasound incumbent and UltraSight partner (Lumify integration). Owns AI ultrasound development capabilities and vast cardiology distribution — represents both the largest commercial opportunity and the most significant competitive threat.

Emerging players

  • Dia Imaging Analysis: AI-powered cardiac ultrasound analysis company focused on automated quantification of echo parameters. Adjacent to UltraSight in the cardiac AI workflow — interpretation layer complementing UltraSight's acquisition layer.
  • Eko Health: AI-augmented cardiac auscultation (digital stethoscope) company pursuing FDA-cleared AI for cardiac disease detection. Adjacent point-of-care cardiology AI for primary/ambulatory use — potential upstream or downstream complement to UltraSight's imaging workflow.
  • HeartVista: Cardiac MRI AI company enabling faster scan acquisition through automated guidance. Targets cardiology AI in a different modality but with parallel workflow philosophy and overlapping customer base in academic cardiology.
  • Intelligent Ultrasound: AI ultrasound simulation and guidance company, publicly traded on AIM. Addresses similar novice-user enablement for ultrasound acquisition with broader (non-cardiac) clinical scope, representing adjacent competition for hospital training budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

UltraSight social profiles

Digital presence

UltraSight compliance and trust

Trust signal

Compliance7 records

UltraSight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

UltraSight leadership team

Management profile

Number of profiles

Profiles13 records

UltraSight subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

UltraSight funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

UltraSight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UltraSight

What does UltraSight do?

UltraSight develops AI-powered real-time guidance software that enables healthcare professionals without prior sonography experience to acquire diagnostic-quality cardiac ultrasound images at the point of care. The software analyzes the ultrasound video stream using geometric deep learning, predicts probe position relative to the heart, and provides 3D graphical guidance on probe maneuvering along with automated image quality assessment. It is designed as an accessory that pairs with compatible point-of-care ultrasound devices from partners such as Philips, Butterfly Network, and EchoNous, and is licensed to healthcare systems, hospitals, and OEMs worldwide.

Is UltraSight a public or private company?

UltraSight is a private company. It is classified as venture growth investor backed and is currently operating.

When was UltraSight founded?

UltraSight was founded in 2018. It employs 11 to 50 people.

Where is UltraSight based?

UltraSight is headquartered in Cambridge, United States, in the North America region.

How does UltraSight make money?

Two revenue lines are on record. AI-Guided Cardiac Ultrasound Software License is the primary driver. The others are joint Venture Revenue - Asia Pacific.

Who are UltraSight's main competitors?

Direct peers on record are Butterfly Network, Ultromics, EchoNous and Caption Health (GE HealthCare). Broad incumbents are GE HealthCare and Philips. Emerging players are Dia Imaging Analysis, Eko Health, HeartVista and Intelligent Ultrasound.

Does UltraSight have an API?

No public API is recorded for UltraSight.

What industry is UltraSight in?

UltraSight's product category is AI Cardiac Ultrasound Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
RuntimewireUltraSight raises $24M to put cardiac ultrasound in more clinicians' handsUltraSight raised $24 million led by Alive HealthTech Growth Fund to expand its AI-guided cardiac ultrasound platform in U.S. hospitals. The company has raised $42 million since 2018, and its software was FDA cleared in December 2025. The capital will fund commercial operations and ICU deployments.The Jerusalem PostAI-guided cardiac sonography firm announces $24 million in financingUltraSight, an Israeli AI-guided cardiac sonography firm, raised $24 million in Series B2 financing led by Alive HealthTech Growth Fund. The funds will support its U.S. market entry and development of new workflows for intensive care and circulatory support. The company's Echosystem platform is used in over 10 commercial sites.HIT ConsultantUltraSight Secures $24M to Scale Point-of-Care Cardiac Ultrasound Across Health SystemsUltraSight raised $24M in Series B2 financing led by Alive HealthTech Growth Fund. The funds will expand its FDA-cleared AI-guided cardiac ultrasound platform across U.S. health systems and develop acute-care workflows. The company is active at over 10 commercial sites.EIN PresswireUltraSight Raises $24 Million to Scale Its AI-Guided Cardiac Workflow Platform Across U.S. Health SystemsUltraSight raised $24 million in Series B2 financing led by Alive HealthTech Growth Fund, with participation from Deep Insight, Star51 Capital, Connecticut Innovations, and eHealth Ventures. The funds will support U.S. commercial expansion and development of new workflows for intensive care and circulatory support settings. The company's Echosystem is deployed across over 10 commercial sites.citybizUltraSight Raises $24M to Expand AI-Guided Cardiac Imaging PlatformUltraSight raised $24 million in Series B2 financing led by Alive HealthTech Growth Fund to expand its AI-guided cardiac imaging platform. The company will use the capital to accelerate U.S. commercialization and develop new workflows for intensive care and circulatory support. Its FDA-cleared Echosystem is deployed at over 10 commercial sites.ynetnewsIsraeli cardiac AI startup UltraSight raises $24 million to expand across US hospitalsUltraSight raised $24 million in Series B2 financing led by Alive HealthTech Growth Fund to expand its AI-guided cardiac ultrasound platform across U.S. hospitals. The company's Echosystem is deployed at over 10 commercial sites, and a JAMA Cardiology study showed 93% sensitivity and 96% specificity for novice operators.FinSMEsUltraSight Raises $24M in Series B2 FundingUltraSight raised $24M in Series B2 financing led by Alive HealthTech Growth Fund. The Boston-based AI cardiac workflow company will use the funds for U.S. commercial expansion and development of new workflows for intensive care and circulatory support. The Echosystem is deployed across over 10 commercial sites.UltrasightUltraSight Raises $24 Million to Scale Its AI-Guided Cardiac Workflow Platform Across U.S. Health SystemsUltraSight raised $24 million in Series B2 financing led by Alive HealthTech Growth Fund. The funds will support U.S. commercial expansion and development of new workflows for intensive care and circulatory support. The company's Echosystem is deployed across over 10 commercial sites.The Des Moines RegisterUltraSight Raises $24 Million to Scale Its AI-Guided Cardiac Workflow Platform Across U.S. Health SystemsUltraSight raised $24 million in Series B2 financing led by Alive HealthTech Growth Fund. The funds will support U.S. commercial expansion and development of new workflows for intensive care and circulatory support. The Echosystem is deployed across over 10 commercial sites.The National Law ReviewUltraSight Raises $24 Million to Scale Its AI-Guided Cardiac WorkUltraSight raised $24 million in Series B2 financing led by Alive HealthTech Growth Fund. The funds will support U.S. commercial expansion and development of new workflows for intensive care and circulatory support. The Echosystem is deployed across over 10 commercial sites.